Other statutory disclosures continued Strategic report
Group companies In accordance with Section 409 of the Companies Act 2006 a full list of subsidiaries, associates, joint ventures and joint arrangements, the country of incorporation and effective percentage of equity owned, as at 31 December 2015 are disclosed below. Unless otherwise stated the share capital disclosed comprises ordinary shares which are indirectly held by GlaxoSmithKline plc. All subsidiary companies are resident for tax purposes in their country of incorporation unless otherwise stated.
Governance & remuneration Financial statements Investor information
Name
Country of incorporation
Effective % Ownership
Wholly owned subsidiaries 1506369 Alberta ULC Action Potential Venture Capital Limited Adechsa GmbH Affymax Research Institute Alenfarma – Especialidades Farmaceuticas, Limitada (iv) Allen & Hanburys Limited (iv) Allen & Hanburys Pharmaceutical Nigeria Limited Allen Farmaceutica, S.A. Allen Pharmazeutika Gesellschaft m.b.H. Aners S.A (iv)
Canada England & Wales Switzerland United States Portugal England & Wales Nigeria Spain Austria Argentina
100 100 100 100 100 100 100 100 100 100
Barrier Therapeutics, Inc. Beecham Group p l c Beecham Pharmaceuticals (Pte) Limited Beecham Pharmaceuticals S.A (iv) (vi) Beecham Portuguesa-Produtos Farmaceuticos e Quimicos, Lda Beecham S.A. (iv) Biddle Sawyer Limited Biovesta Ilaçlari Ltd. Sti. Burroughs Wellcome & Co (Australia) Pty Limited (iv) (vi) Burroughs Wellcome & Co (Bangladesh) Limited Burroughs Wellcome International Limited Caribbean Chemical Company, Ltd. (will be struck off on 31.03.16) Cascan GmbH & Co. KG Castleton Investment Ltd (vi) Cellzome GmbH Cellzome Limited Cellzome Therapeutics, Inc. (iv) Cellzome, Inc.
United States England & Wales Singapore Ecuador Portugal Belgium India Turkey Australia Bangladesh England & Wales Cayman Islands
100 100 100 100 100 100 100 100 100 100 100 100
Germany Mauritius Germany England & Wales United States United States
100 100 100 100 100 100
Charles Midgley Limited (iv)
England & Wales
100
Clarges Pharmaceuticals Limited
England & Wales
100
Colleen Corporation Corixa Corporation Coulter Pharmaceutical, Inc. (iv) Dealcyber Limited Desarrollo Energia Solar Alternativa S.L. Domantis Limited Duncan Flockhart Australia Pty Limited (iv) (vi) Duncan Pharmaceuticals Philippines Inc. Edinburgh Pharmaceutical Industries Limited Eskaylab Limited Etex Farmaceutica Ltda Europharm Holding S.A. Europharm S.A. Fedialis Medica S.A.S. Fipar (Thailand) Ltd (In liquidation) Genelabs Technologies, Inc. Glaxo AS (iv) Glaxo Group Limited Glaxo Kabushiki Kaisha (iv)
United States United States United States England & Wales Spain England & Wales Australia Philippines Scotland England & Wales Chile Romania Romania France Thailand United States Norway England & Wales Japan
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
250 GSK Annual Report 2015
Security
Common Ordinary Ordinary Common Ordinary Quota Ordinary Ordinary Ordinary Ordinary Non-endorsable Nominative Ordinary Common 20p Shares 'A'; 5p Shares B Ordinary Nominative Ordinary Quota Ordinary Equity Nominative Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Series A Preferred Series B Preferred Series C-1 Convertible Preferred Series C-3 Convertible Preferred Ordinary Cumulative Preference Ordinary Preference Shares – No Par Value (Common) Common Common Ordinary Ordinary Ordinary Ordinary Common Ordinary; Preference 10p Ordinary Social Capital Nominative Nominative Ordinary Ordinary Common Ordinary Ordinary Ordinary
% Held by Class of Share
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99.97 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
Wholly owned subsidiaries continued Glaxo Laboratories (Nigeria) Limited (iv) Glaxo Laboratories Limited (iv) Glaxo Operations UK Limited Glaxo Properties BV Glaxo Verwaltungs GmbH (vi) Glaxo Wellcome Australia Pty Ltd (iv) (vi) Glaxo Wellcome Ceylon Limited
Nigeria England & Wales England & Wales Netherlands Germany Australia Sri Lanka
100 100 100 100 100 100 100
Glaxo Wellcome Farmaceutica, Limitada Glaxo Wellcome Holdings Limited (In liquidation) Glaxo Wellcome International B.V. (v) Glaxo Wellcome Manufacturing Pte Ltd Glaxo Wellcome Production S.A.S. Glaxo Wellcome PST Pty Ltd (iv) (vi) Glaxo Wellcome UK Limited Glaxo Wellcome Vidhyasom Limited (iv) Glaxo Wellcome, S.A. Glaxo, S.A. Glaxo-Allenburys (Nigeria) Limited (iv) Glaxochem (UK) Unlimited
Portugal England & Wales Netherlands Singapore France Australia England & Wales Thailand Spain Spain Nigeria England & Wales
100 100 100 100 100 100 100 100 100 100 100 100
Glaxochem Pte Ltd (v) GlaxoSmithKline – Produtos Farmaceuticos, Limitada GlaxoSmithKline (Cambodia) Co., Ltd. GlaxoSmithKline (China) Investment Co Ltd GlaxoSmithKline (China) R&D Company Limited GlaxoSmithKline (Cyprus) Limited GlaxoSmithKline (GSK) S.R.L. GlaxoSmithKline (Ireland) Limited (ii) GlaxoSmithKline (Israel) Ltd GlaxoSmithKline (Malta) Limited GlaxoSmithKline (Private) Limited (iv) GlaxoSmithKline (Thailand) Limited GlaxoSmithKline A.E.B.E. GlaxoSmithKline AB GlaxoSmithKline AG GlaxoSmithKline Algérie S.P.A. GlaxoSmithKline Argentina S.A. GlaxoSmithKline AS GlaxoSmithKline Asia Pvt. Limited GlaxoSmithKline Australia Pty Ltd GlaxoSmithKline B.V. GlaxoSmithKline Beteiligungs GmbH GlaxoSmithKline Biologicals (Shanghai) Ltd. GlaxoSmithKline Biologicals (Shenzhen) Co., Ltd (iv) GlaxoSmithKline Biologicals Kft. GlaxoSmithKline Biologicals S.A.S. GlaxoSmithKline Biologicals SA GlaxoSmithKline Brasil Limitada GlaxoSmithKline Business Services S.A. (iv) (vi) GlaxoSmithKline Capital Inc. GlaxoSmithKline Capital plc GlaxoSmithKline Caribbean Limited GlaxoSmithKline Chile Farmaceutica Limitada GlaxoSmithKline Colombia S.A. GlaxoSmithKline Consumer Healthcare Investments (Ireland) Limited (ii) (v) GlaxoSmithKline Consumer Healthcare Ireland IP Limited (ii) (v) GlaxoSmithKline Consumer Healthcare Pakistan Limited GlaxoSmithKline Consumer Healthcare Sri Lanka Holdings Limited (iv) GlaxoSmithKline Consumer Holding B.V. GlaxoSmithKline d.o.o
Singapore Portugal Cambodia China China Cyprus Romania Ireland Israel Malta Zimbabwe Thailand Greece Sweden Switzerland Algeria Argentina Norway India Australia Netherlands Germany China China Hungary France Belgium Brazil Costa Rica United States England & Wales England & Wales Chile Colombia Ireland
% Held by Class of Share
Security
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary B Ordinary Quota Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary B Ordinary C Ordinary Ordinary Quota Ordinary Ordinary Equity Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Equity Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary; Preference Ordinary Ordinary Ordinary Ordinary Ordinary Social Capital Ordinary Ordinary
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
Ireland Pakistan England & Wales
100 100 100
Ordinary Ordinary Ordinary
100 100 100
Netherlands Bosnia and Herzegovina
100 100
Ordinary Euro Quota
100 100
GSK Annual Report 2015 251
Investor information
Effective % Ownership
Financial statements
Country of incorporation
Governance & remuneration
Name
Strategic report
Group companies continued
Other statutory disclosures continued Strategic report
Group companies continued
Governance & remuneration Financial statements Investor information
Name
Country of incorporation
Effective % Ownership
Wholly owned subsidiaries continued GlaxoSmithKline d.o.o. GlaxoSmithKline doo Beograd GlaxoSmithKline Ecuador S.A. GlaxoSmithKline Eesti OU GlaxoSmithKline ehf GlaxoSmithKline El Salvador S.A. de C.V. GlaxoSmithKline EOOD GlaxoSmithKline Export Limited GlaxoSmithKline Export Panama S.A. GlaxoSmithKline Far East B.V. GlaxoSmithKline Finance plc GlaxoSmithKline GmbH & Co. KG GlaxoSmithKline Guatemala S.A. GlaxoSmithKline Holding AS GlaxoSmithKline Holdings (Americas) Inc. GlaxoSmithKline Holdings (Ireland) Limited GlaxoSmithKline Holdings (One) Limited (i) GlaxoSmithKline Holdings Limited (i) GlaxoSmithKline Holdings Pty Ltd GlaxoSmithKline Honduras S.A. GlaxoSmithKline IHC Limited GlaxoSmithKline Ilaclari Sanayi ve Ticaret A.S. GlaxoSmithKline Inc.
Croatia Serbia Ecuador Estonia Iceland El Salvador Bulgaria England & Wales Panama Netherlands England & Wales Germany Guatemala Norway United States England & Wales England & Wales England & Wales Australia Honduras England & Wales Turkey Canada
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
GlaxoSmithKline Insurance Ltd. GlaxoSmithKline Intellectual Property (No.2) Limited GlaxoSmithKline Intellectual Property Development Limited GlaxoSmithKline Intellectual Property Holdings Limited GlaxoSmithKline Intellectual Property Limited GlaxoSmithKline Intellectual Property Management Limited GlaxoSmithKline International Limited GlaxoSmithKline Investigación y Desarrollo, S.L. GlaxoSmithKline Investment Holdings Limited GlaxoSmithKline Investment Services Limited GlaxoSmithKline Investments (Ireland) Limited (ii) (v) GlaxoSmithKline Investments Pty Ltd GlaxoSmithKline K.K. GlaxoSmithKline Korea Limited GlaxoSmithKline Latin America, S.A. GlaxoSmithKline Latvia SIA GlaxoSmithKline Lietuva UAB GlaxoSmithKline Limited GlaxoSmithKline LLC GlaxoSmithKline Manufacturing SpA GlaxoSmithKline Maroc S.A. GlaxoSmithKline Medical and Healthcare Products Limited GlaxoSmithKline Mercury Limited (i) GlaxoSmithKline Mexico S.A. de C.V. GlaxoSmithKline NZ Limited GlaxoSmithKline Oy GlaxoSmithKline Peru S.A. GlaxoSmithKline Pharma A/S GlaxoSmithKline Pharma GmbH GlaxoSmithKline Pharmaceutical Kenya Limited GlaxoSmithKline Pharmaceutical Nigeria Limited GlaxoSmithKline Pharmaceutical Sdn Bhd GlaxoSmithKline Pharmaceuticals (Pvt) Ltd (iv) GlaxoSmithKline Pharmaceuticals (Suzhou) Limited GlaxoSmithKline Pharmaceuticals Costa Rica S.A GlaxoSmithKline Pharmaceuticals S.A.
Bermuda England & Wales England & Wales England & Wales England & Wales England & Wales England & Wales Spain England & Wales England & Wales Ireland Australia Japan South Korea Panama Latvia Lithuania Hong Kong United States Italy Morocco Hungary England & Wales Mexico New Zealand Finland Peru Denmark Austria Kenya Nigeria Malaysia Sri Lanka China Costa Rica Poland
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
252 GSK Annual Report 2015
Security
Equity Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Partnership Capital Ordinary Ordinary Common Ordinary; Deferred Ordinary Ordinary Ordinary Ordinary Ordinary Nominative Class A Common Class C Preference Ordinary Ordinary Ordinary A Ordinary; B Ordinary Ordinary; Deferred Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary LLC Interests Ordinary Ordinary Ordinary Quotas Ordinary Ordinary A; Ordinary B Ordinary Ordinary Ordinary Class A Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary A; Ordinary B; Ordinary C; Ordinary D
% Held by Class of Share
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
Wholly owned subsidiaries continued GlaxoSmithKline Pharmaceuticals SA GlaxoSmithKline Pharmaceuticals Ukraine LLC GlaxoSmithKline Philippines Inc GlaxoSmithKline Pte Ltd GlaxoSmithKline Puerto Rico Inc. (iv) GlaxoSmithKline Republica Dominicana S.A. GlaxoSmithKline Research & Development Limited GlaxoSmithKline S.A. GlaxoSmithKline S.p.A. GlaxoSmithKline s.r.o. GlaxoSmithKline Services GmbH & Co. KG (vi) GlaxoSmithKline Services Inc. (iv) GlaxoSmithKline Services Unlimited (i) GlaxoSmithKline SL Holdings, LLC GlaxoSmithKline SL LLC GlaxoSmithKline SL LP (iv) GlaxoSmithKline Slovakia s.r.o. GlaxoSmithKline South Africa (Pty) Limited GlaxoSmithKline Superannuation Company Pty Ltd (iv) (vi) GlaxoSmithKline Trading Services Limited (ii) (v) GlaxoSmithKline Trading ZAO GlaxoSmithKline Tunisia S.A.R.L. GlaxoSmithKline UK Limited GlaxoSmithKline Uruguay S.A.
Belgium Ukraine Philippines Singapore Puerto Rico Dominican Republic England & Wales Spain Italy Czech Republic Germany United States England & Wales United States United States England & Wales Slovakia South Africa Australia Ireland Russia Tunisia England & Wales Uruguay
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
GlaxoSmithKline Venezuela C.A. GlaxoSmithKline Vietnam Limited Liability Company (iv) Glycovaxyn AG (iv) (vi)
Venezuela Vietnam Switzerland
100 100 100
Group Laboratories South Africa (Pty) Limited (iv) (vi) Groupe GlaxoSmithKline S.A.S. GSK Business Service Centre Sdn Bhd GSK Commercial Sp. z o.o. GSK d.o.o., Ljubljana GSK Employee Share Plan Pty Ltd GSK Kazakhstan LLP GSK Services Sp z o.o. GSK Vaccines GmbH GSK Vaccines Institute for Global Health S.r.l. GSK Vaccines S.r.l. GSK Vaccines Vertriebs GmbH Herbridge (ii) (iv) (vi) HGS France S.a.r.l. HGS Luxembourg LLC (iv) (vi) Horlicks Limited Human Genome Sciences Pacific Pty Ltd (vi) Human Genome Sciences, Inc. ID Biomedical Corporation of Quebec ID Biomedical Corporation of Washington (iv) Instituto Luso Farmaco, Limitada (iv) InterPharma Dienstleistungen GmbH J&J Technologies, LC (iv) Laboratoire GlaxoSmithKline Laboratoire Pharmaceutique Algérien LPA Production SPA Laboratoire Pharmaceutique Algérien SPA Laboratoires Paucourt (iv) Laboratoires Saint-Germain (iv) Laboratorios Dermatologicos Darier, S.A de C.V. Laboratorios Farmaceuticos Stiefel (Portugal) LTDA (iv) Laboratorios Phoenix Sociedad Anonima Industrial Comercial Y Financiera Laboratorios Stiefel de Chile & CIA LTDA Laboratorios Stiefel de Venezuela SA
South Africa France Malaysia Poland Slovenia Australia Kazakhstan Poland Germany Italy Italy Germany Ireland France United States England & Wales Australia United States Canada United States Portugal Austria United States France Algeria Algeria France France Mexico Portugal Argentina
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
Chile Venezuela
100 100
% Held by Class of Share
Security
Ordinary Chartered Capital Common Ordinary Common Ordinary Ordinary Ordinary Ordinary Ordinary Partnership Capital Common Ordinary LLC Interests LLC Interests Partnership Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Registered Shares Provisory Stock Ordinary Equity Capital Common; Preferred A, Preferred B; Preferred C Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Partnership Interest Ordinary Ordinary Quota Quota Ordinary Ordinary Ordinary Common Interests Ordinary Ordinary Common Common Common Ordinary Quota Quota Membership Interest Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary A; Ordinary B Ordinary Quota Non-endorsable Nominative Ordinary Shares Social Capital Ordinary
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
GSK Annual Report 2015 253
Investor information
Effective % Ownership
Financial statements
Country of incorporation
Governance & remuneration
Name
Strategic report
Group companies continued
Other statutory disclosures continued Strategic report
Group companies continued
Governance & remuneration
Name
Country of incorporation
Effective % Ownership
Wholly owned subsidiaries continued Laboratorios Stiefel Ltda. Laboratorios Wellcome De Portugal Limitada (iv) Laboratorios Wellcome S.A. (In liquidation) Maxinutrition Limited (In liquidation) Mixis Genetics Limited
Brazil Portugal Uruguay England & Wales England & Wales
100 100 100 100 100
Montrose Fine Chemical Company Ltd Montrose Pharma Company Limited Montrose Pharma UAB (iv) Nanjing Meirui Pharma Co. Ltd Novartis Vaccines and Diagnostics AG (vi) Novartis Vaccines and Diagnostics Pty Ltd Novartis Vaccines and Diagnostics S.L. (vi) Okairos AG (iv) (vi)
Scotland Hungary Lithuania China Switzerland Australia Spain Switzerland
100 100 100 100 100 100 100 100
Penn Labs Inc. (iv) S.R. One International B.V. S.R. One, Limited Setfirst Limited Smith Kline & French Laboratories Limited Smith Kline & French Portuguesa-Produtos Farmaceuticos, LDA (iv) SmithKline Beecham (Australia) Pty Ltd (iv) (vi) SmithKline Beecham (Bangladesh) Private Limited (iv) SmithKline Beecham (Cork) Limited (ii) SmithKline Beecham (Export) Limited SmithKline Beecham (H) Limited
United States Netherlands United States England & Wales England & Wales Portugal
100 100 100 100 100 100
Australia Bangladesh Ireland England & Wales England & Wales
100 100 100 100 100
Financial statements Investor information
SmithKline Beecham (Investments) Limited SmithKline Beecham (Manufacturing) Limited (ii) SmithKline Beecham (SWG) Limited SmithKline Beecham Animal Health Company SmithKline Beecham Biologicals US Partnership SmithKline Beecham Egypt L.L.C. SmithKline Beecham Farma, S.A. SmithKline Beecham Holdings (Australia) Pty. Limited (iv) (vi) SmithKline Beecham Inter-American Corporation (iv) SmithKline Beecham Limited SmithKline Beecham Marketing and Technical Services Limited SmithKline Beecham Nominees Limited SmithKline Beecham Overseas Limited SmithKline Beecham Pension Plan Trustee Limited (iv) SmithKline Beecham Pension Trustees Limited (iv) SmithKline Beecham Pharma GmbH & Co KG SmithKline Beecham Pharma Verwaltungs GmbH SmithKline Beecham Pharmaceuticals (Pty) Limited (iv) (vi) SmithKline Beecham Pharmaceuticals Co. SmithKline Beecham Port Louis Limited (vi) SmithKline Beecham Retirement Plan (Nominees) Pty Limited (iv) (vi) SmithKline Beecham Senior Executive Pension Plan Trustee Limited (iv) Stiefel Distributors (Ireland) Limited (ii) (iv) Stiefel Dominicana SRL (iv) Stiefel Farma, S.A Stiefel GmbH & Co. KG Stiefel India Private Limited Stiefel Laboratories (Ireland) Limited (ii) Stiefel Laboratories (Maidenhead) Ltd Stiefel Laboratories (Thailand) Ltd. (Liquidated 25 Jan 2016) Stiefel Laboratories (U.K.) Ltd Stiefel Laboratories Limited (iv)
254 GSK Annual Report 2015
Security
% Held by Class of Share
Ordinary Ordinary Quota Ordinary Ordinary Ordinary Ordinary Euro Ordinary Ordinary Quota Ordinary Ordinary Ordinary Ordinary Ordinary Common; Preferred A; Preferred B Common Ordinary Units (Common) Ordinary Ordinary Ordinary Quota
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
England & Wales Ireland England & Wales Canada United States Egypt Spain Australia United States England & Wales England & Wales England & Wales England & Wales England & Wales England & Wales Germany Germany South Africa United States Mauritius Australia
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
Ordinary Ordinary Ordinary Ordinary Non-Cumulative Non-Redeemable Ordinary Ordinary Ordinary Ordinary Common Partnership Interests Quotas Ordinary Ordinary A; Ordinary B Shares No par Value (Common) Ordinary 6.25p Ordinary Ordinary Ordinary Ordinary Ordinary Partnership Capital Ordinary Ordinary Shares No par Value (Common) Ordinary Ordinary
England & Wales
100
Ordinary
100
Ireland Dominican Republic Spain Germany India Ireland England & Wales Thailand England & Wales England & Wales
100 100 100 100 100 100 100 100 100 100
Ordinary Ordinary Quotas Ordinary Partnership Capital Equity Ordinary Ordinary Ordinary; Preference Ordinary Ordinary
100 100 100 100 100 100 100 100 100 100
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
Wholly owned subsidiaries continued Stiefel Laboratories Pte Limited Stiefel Laboratories Pty Ltd (iv) (vi) Stiefel Laboratories SA (Pty) Ltd (iv) (vi) Stiefel Laboratories Taiwan Ltd (Liquidated 5 Jan 2016) Stiefel Laboratories, Inc. Stiefel Maroc SARL Stiefel Polska SP Z O.O. w likwidacji (In liquidation) Stiefel Research (Australia) Holdings Pty Ltd (iv) Stiefel Research Australia Pty Ltd Stiefel Research Institute, Inc. (vi) Stiefel Sales, Inc. (iv) (vi) Stiefel West Coast LLC Strebor Inc. Tempero Pharmaceuticals, Inc.
Singapore Australia South Africa Taiwan United States Morocco Poland Australia Australia United States United States United States United States United States
100 100 100 100 100 100 100 100 100 100 100 100 100 100
The Sydney Ross Co. (iv) The Wellcome Foundation Limited UCB Pharma (Thailand) Ltd (Liquidated 25 Jan 2016) UCB Pharma Asia Pacific Sdn Bhd (iv) Webderm, Inc. (iv) (vi) Wellcome Consumer Healthcare Limited (iv) Wellcome Consumer Products Limited (iv) Wellcome Developments Pty Ltd (iv) (vi) Wellcome Limited Wellcome Operations Pty Ltd (iv) (vi)
United States England & Wales Thailand Malaysia United States England & Wales England & Wales Australia England & Wales Australia
100 100 100 100 100 100 100 100 100 100
Ordinary Ordinary Ordinary Ordinary Common Ordinary Ordinary Ordinary Ordinary Common Common LLC Interests USD 1 par value (Common) Series A Preference Series B Preference; Common Ordinary Ordinary Ordinary Ordinary Common Ordinary Ordinary Ordinary Ordinary Ordinary
Egypt United States United States England & Wales United States Slovakia Philippines Puerto Rico Switzerland
99.5 55.9 63.5 50 63.5 63.5 63.5 63.5 63.5
New Monetary Shares Common Common Capital Common No Par Value Ordinary Common Common Capital
Saudi Arabia China Bangladesh Brazil China Hong Kong Ireland England & Wales Thailand England & Wales England & Wales United States Denmark Sweden Switzerland Argentina
49 90 82 63.5 63.5 63.5 63.5 63.5 63.5 63.5 63.5 63.5 63.5 63.5 63.5 63.5
Australia Netherlands Canada Colombia Czech Republic England & Wales Finland Austria Germany
63.5 63.5 63.5 63.5 63.5 63.5 63.5 63.5 63.5
Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary Ordinary LLC Interests Ordinary Ordinary Ordinary Nominative non endorseable Ordinary Ordinary Ordinary A Common Ordinary Ordinary Ordinary Ordinary Ordinary Partnership Capital
Subsidiaries where the effective interest is less than 100% Amoun Pharmaceutical Industries Co. S.A.E. Beecham Enterprises Inc. (iv) Block Drug Company, Inc. British Pharma Group Limited Block Drug Corporation (iv) de Miclén a.s. Duncan Consumer Healthcare Philippines Inc Ex-Lax, Inc. Fondation Novartis Consumer Health Pour I'Avancement Des Sciences Medicales, Biologiques Et Pharmaceutiques Glaxo Saudi Arabia Limited GlaxoSmithKline (Tianjin) Co. Ltd GlaxoSmithKline Bangladesh Limited GlaxoSmithKline Brasil Produtos para Consumo e Saude Ltda GlaxoSmithKline Consumer Healthcare (China) Co. Ltd GlaxoSmithKline Consumer Healthcare (Hong Kong) Limited GlaxoSmithKline Consumer Healthcare (Ireland) Limited (ii) GlaxoSmithKline Consumer Healthcare (Overseas) Limited GlaxoSmithKline Consumer Healthcare (Thailand) Limited GlaxoSmithKline Consumer Healthcare (UK) IP Limited GlaxoSmithKline Consumer Healthcare (UK) Trading Limited GlaxoSmithKline Consumer Healthcare (US) IP LLC GlaxoSmithKline Consumer Healthcare A/S GlaxoSmithKline Consumer Healthcare AB GlaxoSmithKline Consumer Healthcare AG GlaxoSmithKline Consumer Healthcare Argentina S.A. (iv) GlaxoSmithKline Consumer Healthcare Australia Pty ltd GlaxoSmithKline Consumer Healthcare B.V. GlaxoSmithKline Consumer Healthcare Canada Corp GlaxoSmithKline Consumer Healthcare Colombia SAS GlaxoSmithKline Consumer Healthcare Czech Republic s.r.o. GlaxoSmithKline Consumer Healthcare Finance Limited GlaxoSmithKline Consumer Healthcare Finland Oy GlaxoSmithKline Consumer Healthcare GmbH GlaxoSmithKline Consumer Healthcare GmbH & Co. KG
% Held by Class of Share
Security
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
99.5 100 100 50 100 100 100 100 63.5 49 90 82 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
GSK Annual Report 2015 255
Investor information
Effective % Ownership
Financial statements
Country of incorporation
Governance & remuneration
Name
Strategic report
Group companies continued
Other statutory disclosures continued Strategic report
Group companies continued Name
Country of incorporation
Subsidiaries where the effective interest is less than 100% continued GlaxoSmithKline Consumer Healthcare Greece Societe Greece Anonyme GlaxoSmithKline Consumer Healthcare Holdings (US) LLC United States GlaxoSmithKline Consumer Healthcare Holdings Limited England & Wales
Effective % Ownership
Security
% Held by Class of Share
63.5
Ordinary
100
63.5 63.5
100 100 0 100 100 100 100
Governance & remuneration Financial statements Investor information
GlaxoSmithKline Consumer Healthcare Inc.
Canada
63.5
GlaxoSmithKline Consumer Healthcare Investments (Ireland) (No 2) (ii) (v) GlaxoSmithKline Consumer Healthcare Investments (Ireland) (No 3) Limited (ii) (v) GlaxoSmithKline Consumer Healthcare Japan K.K. GlaxoSmithKline Consumer Healthcare Korea Co., Ltd. GlaxoSmithKline Consumer Healthcare L.L.C. GlaxoSmithKline Consumer Healthcare Limited GlaxoSmithKline Consumer Healthcare Mexico, S. De R.L. de C.V. GlaxoSmithKline Consumer Healthcare New Zealand Limited GlaxoSmithKline Consumer Healthcare Norway AS GlaxoSmithKline Consumer Healthcare Philippines Inc GlaxoSmithKline Consumer Healthcare Pte. Ltd. GlaxoSmithKline Consumer Healthcare S.A. GlaxoSmithKline Consumer Healthcare S.A. GlaxoSmithKline Consumer Healthcare S.p.A. GlaxoSmithKline Consumer Healthcare Sdn. Bhd. GlaxoSmithKline Consumer Healthcare Slovakia s. r. o. GlaxoSmithKline Consumer Healthcare South Africa Pty (Ltd) GlaxoSmithKline Consumer Healthcare Sp.z.o.o. GlaxoSmithKline Consumer Healthcare SRL GlaxoSmithKline Consumer Healthcare, L.P. GlaxoSmithKline Consumer Healthcare, Produtos para a Saude e Higiene, Lda GlaxoSmithKline Consumer Nigeria plc (iii) GlaxoSmithKline Consumer Private Limited GlaxoSmithKline Consumer Trading Services Limited GlaxoSmithKline Costa Rica S.A. GlaxoSmithKline Dungarvan Limited (ii) GlaxoSmithKline Healthcare AO GlaxoSmithKline Healthcare GmbH GlaxoSmithKline Healthcare Ukraine O.O.O. GlaxoSmithKline Landholding Company, Inc GlaxoSmithKline Limited GlaxoSmithKline OTC (PVT.) Limited GlaxoSmithKline Pakistan Limited GlaxoSmithKline Panama S.A. GlaxoSmithKline Paraguay S.A. GlaxoSmithKline Pharmaceuticals Limited GlaxoSmithKline S.A.E. GlaxoSmithKline Sante Grand Public SAS GlaxoSmithKline Tuketici Sagligi Anonim Sirketi GlaxoSmithKline-Consumer Hungary Limited Liability Company GSK Consumer Healthcare Singapore Pte. Ltd Iodosan S.p.A. Kuhs GmbH Laboratorios ViiV Healthcare, S.L. Modern Pharma Trading Company L.L.C. Novartis Consumer Health Australasia Pty Ltd
Ireland
63.5
LLC Interests Ordinary A Ordinary B Common Preferred Ordinary
Ireland
63.5
Ordinary
Japan Korea United States India Mexico New Zealand Norway Philippines Singapore Belgium Spain Italy Malaysia Slovakia South Africa Poland Romania United States Portugal
63.5 63.5 63.5 72.5 63.5 63.5 63.5 63.5 63.5 63.5 63.5 63.5 63.5 63.5 63.5 63.5 63.5 55.9 63.5
Ordinary Ordinary LLC Interests Equity Ordinary Ordinary Ordinary Common Ordinary Ordinary Ordinary Ordinary Ordinary Ownership Interest Ordinary Common Ordinary Partnership Interest Ordinary Quota
100 100 100 72.5 100 100 100 100 100 100 100 100 100 100 100 100 100 55.9 100
Nigeria India England & Wales Costa Rica Ireland Russia Germany Ukraine Philippines Kenya Pakistan Pakistan Panama Paraguay India Egypt France Turkey Hungary Singapore Italy Germany Spain Egypt Australia
46.4 63.5 63.5 63.5 63.5 63.5 63.5 63.5 39.9 63.5 63.5 82.6 63.5 63.5 75 91.2 63.5 63.5 63.5 63.5 63.5 63.5 78.3 98.2 63.5
Canada
63.5
Ordinary Equity Ordinary Ordinary Ordinary Ordinary Ordinary Ownership Interest Common Ordinary Ordinary Ordinary Ordinary Ordinary Equity Ordinary Ordinary Nominative Membership Ordinary Ordinary Equity Ordinary Quotas Ordinary Redeemable Preference Common
46.4 100 100 100 100 100 100 100 100 100 100 82.6 100 100 75 91.2 100 100 100 100 100 100 100 98.2 100 100 100
Germany Russia
38.1 63.5
Ordinary Participation Interest
Novartis Consumer Health Canada Inc./Novartis Sante Familiale Canada, Inc. Novartis Consumer Health GmbH Novartis Consumer Health LLC
256 GSK Annual Report 2015
100 100
Name
Country of incorporation
Effective % Ownership
Indonesia
63.5
Panadol GmbH PHIVCO Jersey II Limited (iv) (v) PHIVCO Jersey Limited (iv) (v) PHIVCO UK II Limited PHIVCO UK Limited PHIVCO-1 LLC PHIVCO-2 LLC PT Glaxo Wellcome Indonesia
Germany Jersey Jersey England & Wales England & Wales United States United States Indonesia
63.5 78.3 78.3 78.3 78.3 78.3 78.3 95
PT. Bina Dentalindo (In liquidation) Shionogi-ViiV Healthcare LLC (iv) Sino-American Tianjin Smith Kline & French Laboratories Ltd SmithKline Beecham (Private) Limited SmithKline Beecham Research Limited SmithKline Beecham S.A. SmithKline Beecham-Biomed O.O.O. Stafford-Miller (Ireland) Limited (ii) Stafford-Miller Limited
Indonesia United States China Sri Lanka England & Wales Spain Russia Ireland England & Wales
63.5 78.3 34.9 99.6 63.5 63.5 97 63.5 63.5
Sterling Drug (Malaya) Sdn Berhad Sterling Products International, Incorporated (iv) Stiefel Consumer Healthcare (UK) Limited Stiefel Egypt LLC (iv) Stiefel Manufacturing (Ireland) Limited (ii) ViiV Healthcare (South Africa) (Proprietary) Limited ViiV Healthcare BV ViiV Healthcare Company ViiV Healthcare Finance 1 Limited (iv) ViiV Healthcare Finance 2 Limited (iv) ViiV Healthcare GmbH ViiV Healthcare GmbH ViiV Healthcare Kabushiki Kaisha ViiV Healthcare Limited
Malaysia United States England & Wales Egypt Ireland South Africa Netherlands United States England & Wales England & Wales Germany Switzerland Japan England & Wales
63.5 63.5 63.5 99 63.5 78.3 78.3 78.3 78.3 78.3 78.3 78.3 78.3 78.3
ViiV Healthcare Overseas Limited ViiV Healthcare Pty Ltd ViiV Healthcare Puerto Rico, LLC ViiV Healthcare S.r.l. ViiV Healthcare SAS ViiV Healthcare sprl ViiV Healthcare Trading LLC ViiV Healthcare Trading Services UK Limited ViiV Healthcare UK (No.2) Limited (v) ViiV Healthcare UK (No.3) Limited ViiV Healthcare UK (No.4) Limited (iv) ViiV Healthcare UK Limited
England & Wales Australia Puerto Rico Italy France Belgium Russia England & Wales Jersey England & Wales England & Wales England & Wales
78.3 78.3 78.3 78.3 78.3 78.3 78.3 78.3 78.3 78.3 78.3 78.3
100 100 100 100 100 100 100 60 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 55 99.6 100 100 97 100 100 100 100 100 100 99 100 100 100 100 100 100 100 100 100 100 0 0 0 0 100 100 100 100 100 100 100 100 100 100 100 100
GSK Annual Report 2015 257
Investor information
P.T. Sterling Products Indonesia
Ordinary Ordinary Ordinary Ordinary Registered Shares Ordinary Common Ordinary Ordinary A Shares B Shares A Shares B Shares Ordinary Ordinary Ordinary Ordinary Ordinary LLC Interests LLC Interests A Shares B Shares Ordinary Common Interests Ordinary Ordinary Ordinary Ordinary Participation Interest Ordinary Ordinary Non-Cumulative Non Redeemable Preference Ordinary Common Ordinary Quota Ordinary Ordinary Ordinary Common Ordinary Ordinary Ordinary Ordinary Ordinary Class A Shares Class B Shares Class C Shares Class D1 Preference Class D2 Ordinary Ordinary Ordinary LLC Interests Quota Ordinary Ordinary Participation Interest Ordinary Ordinary Ordinary Ordinary Ordinary
Financial statements
63.5 63.5 63.5 63.5 63.5 63.5 63.5 38.1 63.5 99
Governance & remuneration
Subsidiaries where the effective interest is less than 100% continued Novartis Consumer Health N.V. Belgium Novartis Consumer Health S.A. Spain Novartis Consumer Health S.A. Switzerland Novartis Consumer Health Schweiz AG Switzerland Novartis Consumer Health Services S.A. Switzerland Novartis Consumer Health UK Limited England & Wales Novartis Consumer Health, Inc. United States Novartis Consumer Health-Gebro GmbH Austria Novartis Sante Familiale S.A.S. (In liquidation) France P.T. SmithKline Beecham Pharmaceuticals Indonesia
% Held by Class of Share
Security
Strategic report
Group companies continued
Other statutory disclosures continued Strategic report
Group companies continued Country of incorporation
Governance & remuneration
Effective % Ownership
Security
Subsidiaries where the effective interest is less than 100% continued ViiV Healthcare ULC Canada ViiV Healthcare Venture LLC United States ViiV HIV Healthcare Unipessoal Lda Portugal Winster Pharmaceuticals Limited Nigeria Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd China
78.3 78.3 78.3 46.4 95
Common LLC Interests Quota Ordinary Ordinary
Associates Calci Medica Inc. Index Ventures Life VI (Jersey) LP Theravance, Inc. (now Innoviva, Inc.) JCR Pharmaceuticals Co. Ltd Kurma Biofund II, FCPR Longwood Founders Fund LP River Vision Development Corp.
United States United States United States Japan France United States United States
33.9 25 27.8 24.6 32 28 33
Series A and Junior Preferred Partnership Interest Common Common Partnership Interest Partnership Interest Series A Preferred
Joint Ventures Chiron Panacea Vaccines Private Ltd (In liquidation) Japan Vaccine Co., Ltd Japan Vaccine Distribution Co., Ltd Qualivax Pte Limited Qura Therapeutics LLC
India Japan Japan Singapore United States
50 50 50 50 50
Name
% Held by Class of Share
Key (i) (ii) Financial statements
(iv) (v)
Directly owned by GlaxoSmithKline plc. Exempt from the provisions of section 347 and 348 of the Companies Act 2014 (Ireland), in accordance with the exemptions noted in Section 357 of that Act. Consolidated as a subsidiary in accordance with section 1162 (4)(a) of the Companies Act 2006 on the grounds of dominant influence. Dormant company. Tax resident in the UK.
(vi)
Entity expected to be disposed of or removed in 2016.
(iii)
Investor information 258 GSK Annual Report 2015
100 100 100 100 95
33.9 25 27.8 24.6 32 28 33
